Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above 200 Day Moving Average of $4.40

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.40 and traded as high as $4.58. Achieve Life Sciences shares last traded at $4.38, with a volume of 63,124 shares changing hands.

Wall Street Analysts Forecast Growth

ACHV has been the topic of several research reports. Oppenheimer reissued an “outperform” rating and set a $18.00 price target on shares of Achieve Life Sciences in a research report on Monday, April 1st. Lake Street Capital dropped their price target on Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, March 5th.

Achieve Life Sciences Price Performance

The company has a debt-to-equity ratio of 4.02, a current ratio of 0.82 and a quick ratio of 0.82. The company has a 50-day simple moving average of $4.41 and a two-hundred day simple moving average of $4.40. The stock has a market capitalization of $150.02 million, a price-to-earnings ratio of -2.86 and a beta of 1.32.

Institutional Investors Weigh In On Achieve Life Sciences

Several large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its position in Achieve Life Sciences by 75.6% in the first quarter. Tower Research Capital LLC TRC now owns 3,646 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 1,570 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Achieve Life Sciences by 6.1% during the first quarter. Renaissance Technologies LLC now owns 41,600 shares of the biopharmaceutical company’s stock valued at $283,000 after purchasing an additional 2,400 shares during the period. State Street Corp increased its holdings in shares of Achieve Life Sciences by 26.9% during the first quarter. State Street Corp now owns 18,731 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 3,970 shares during the period. Northern Trust Corp increased its holdings in shares of Achieve Life Sciences by 7.3% during the third quarter. Northern Trust Corp now owns 78,957 shares of the biopharmaceutical company’s stock valued at $340,000 after purchasing an additional 5,379 shares during the period. Finally, Manchester Financial Inc. increased its holdings in shares of Achieve Life Sciences by 43.9% during the third quarter. Manchester Financial Inc. now owns 18,600 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 5,675 shares during the period. 33.52% of the stock is owned by institutional investors and hedge funds.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.